Effects of various vehicles and fatty acids on the skin permeation of lornoxicam

다국어 초록 (Multilingual Abstract)

Transdermal permeation of lornoxicam, one of potent non-steroidal anti-inflammatory drugs, was studied in vitro with various vehicles and fatty acids using hairless mouse dorsal skin and human cadaver full skin. Vehicles used were diethylene glycol monoethyl ether (DGME),propylene glycol monocaprylate, propylene glycol, oleyl alcohol, dimethyl sulfoxide (DMSO) and others. Various fatty acids were employed as enhancers. Among pure vehicles studied, only DMSO showed permeation from saturated solutions. In the case of DMSO–DGME co-solvent,the higher the DGME ratios were, the lower the fluxes were. The addition of fatty acid (3 w/v %) increased the permeation in the rank order of linoleic acid (LOA) C oleic acid C lauric acid[capric acid[caprylic acid.
Enhancement ratios ranged from 2 to 37 compared to the flux without fatty acid. Lornoxicam flux decreased in inverse proportion to the concentration of triethanolamine (TEA), which was used as a salt former and solubilizer.
However, the flux increased linearly as the donor dose increased even in the presence of TEA. Using human cadaver skin, the permeability of lornoxicam was much lower than that using the hairless mouse skin, but fluxes increased as the concentration of LOA increased. These results indicate the feasibility of lornoxicam transdermal delivery with a combination of fatty acid and TEA in DMSO or DMSO–DGME cosolvents.

참고문헌 (Reference)

1 Homdrum EM, "Xefo Rapid: a novel effectivetool for pain treatment" 38 : 342-352, 2006

2 Gorukanti SR, "Transdermal delivery ofantiparkinsonian agent, benztropine. I. effect of vehicles on skinpermeation" 192 : 159-172, 1999

3 Kligman AM, "Topical pharmacology and toxicology ofdimethyl sulfoxide" 193 : 796-804, 1965

4 Ammar HO, "Topical liquid crystalline gel containing lornoxicam/cyclodextrincomplex" 73 : 161-175, 2012

5 Fang L, "The use ofcomplexation with alkanolamines to facilitate skin permeation ofmefenamic acid" 262 : 13-22, 2003

6 McCormack K, "The evolving NSAID: focus on lornoxicam" 6 : 262-278, 1999

7 Fang L, "The enhancing effect of a triethanolamineethanol-isopropyl myristate mixed system on the skin permeationof acidic drugs" 25 : 1339-1344, 2002

8 Nanayakkara GR, "The effect of unsaturated fatty acids in benzylalcohol on the percutaneous permeation of three model penetrants" 301 : 129-139, 2005

9 Kanikkannan N, "Structures activity relationship of chemical penetration enhancersin transdermal drug delivery" 7 : 593-608, 2000

10 Sato K, "Species differences inpercutaneous absorption of nicorandil" 80 : 104-107, 1991

11 Golden GM, "Role of stratum corneumlipid fluidity in transdermal drug flux" 76 : 25-28, 1987

12 Wang MY, "Role of solvent ininteractions between fatty acids based formulations and lipidsin porcine stratum corneum" 94 : 207-216, 2004

13 Bonnabry P, "Role of human livermicrosomal CYP2C9 in the biotransformation of lornoxicam" 9 : 305-308, 1996

14 Oertel RP, "Protein conformational changes induced in humanstratum corneum by organic sulfoxides: an infrared spectroscopicinvestigation" 16 : 2329-2345, 1977

15 Hitzenberger G, "Pharmacokineticsof lornoxicam in man" 66 : 22-26, 1990

16 Williams AC, "Penetration enhancers" 56 : 603-618, 2004

17 Pruss TP, "Overview of the pharmacological properties, pharmacokineticsand animal safety assessment of lornoxicam" 66 (66): 18-21, 1990

18 Balfour JA, "Lornoxicam: a review ofits pharmacology and therapeutic potential in the management ofpainful and inflammatory conditions" 51 : 639-657, 1996

19 Wester RC, "In vivo methods for percutaneousabsorption measurements, In Percutaneous Absorption: Mechanisms, Methodology, DrugDelivery, 2nd edn" Marcel Dekker 215-237, 1989

20 Tanojo H, "In vitrohuman skin barrier modulation by fatty acids: skin permeationand thermal analysis studies" 14 : 42-49, 1997

21 Komata Y, "In vitro percutaneousabsorption of thiamine disulfide through rat skin from a mixtureof propylene glycol and fatty acid or its analog" 40 : 2173-2176, 1992

22 Mura P, "Evaluation oftranscutol as a clonazepam transdermal permeation enhancerfrom hydrophilic gel formulations" 9 : 365-372, 2000

23 Ganem-Quintanar A, "Evaluation of the transepidermal permeation of diethylene glycolmonoethyl ether and skin water loss" 147 : 165-172, 1997

24 Gwak HS, "Effects of vehicles and penetrationenhancers on the in vitro percutaneous absorption of tenoxicamthrough hairless mouse skin" 236 : 57-64, 2002

25 Komata Y, "Effect of fatty acid on theaccumulation of thiamine disulfide in rat skin" 17 : 705-708, 1994

26 Buritova J, "Dose-related anti-inflammatory/analgesic effects of lornoxicam: a spinal c-Fos protein study inthe rat" 47 : 18-25, 1998

27 Cable CG, "Dimethyl sulfoxide, In Handbook of pharmaceutical excipients, 4th edn" American Pharmaceutical Association 219-221, 2003

28 Sahoo M, "Development and validation of a RPHPLC-PDA method for simultaneous determination of lornoxicamand thiocolchicoside in pharmaceutical dosage form and itsapplication for dissolution study" 2 : 1-7, 2011

29 Barry BW, "Dermatological formulations" Marcel Dekker 49-94, 1983

30 Skjodt NM, "Clinical pharmacokinetics of lornoxicam.a short half-life oxicam" 34 : 421-428, 1998

31 Pathan IB, "Chemical penetration enhancers fortransdermal drug delivery system" 8 : 173-179, 2009